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Summary Patent foramen ovale and obstructive sleep apnoea are frequently encountered
in the general population. Owing to their prevalence, they may coexist fortuitously; however,
the prevalence of patent foramen ovale seems to be higher in patients with obstructive sleep
apnoea. We have reviewed the epidemiological data, pathophysiology, and the diagnostic and
therapeutic options for both patent foramen ovale and obstructive sleep apnoea. We focus on
the interesting pathophysiological links that could explain a potential association between both
pathologies and their implications, especially on the risk of stroke.
© 2011 Elsevier Masson SAS. All rights reserved.MOTS CLÉS
Foramen ovale
perméable
Résumé Le foramen ovale perméable et le syndrome d’apnées obstructives du sommeil sont
fréquemment rencontrés dans la population générale. En raison de leur prévalence, ils peuvent
coexister fortuitement mais la prévalence du foramen ovale perméable semble néanmoins être
Abbreviations: AHA, American Heart Association; AHI, apnoea-hypopnoea index; ASA, atrial septal aneurysm; CI, conﬁdence interval;
PAP, continuous positive airway pressure; ESO, European Stroke Organisation; FDA, Food and Drug Administration; HR, hazard ratio; OR,
dds ratio; OSA, obstructive sleep apnoea; PFO, patent foramen ovale; POS, platypnoea and orthodeoxia syndrome; TIA, transient ischaemic
ttack; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography.
∗ Corresponding author.
E-mail address: eric.eeckhout@chuv.ch (E. Eeckhout).
875-2136/$ — see front matter © 2011 Elsevier Masson SAS. All rights reserved.
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Syndrome d’apnées
du sommeil ;
Accident vasculaire
cérébral
plus élevée chez les patients présentant un syndrome d’apnées obstructives du sommeil. Nous
passons en revue dans cet article la physiopathologie, le diagnostic et les options thérapeutiques
du syndrome d’apnées obstructives du sommeil ainsi que du foramen ovale perméable. Nous
mettons l’accent sur les liens physiopathologiques qui peuvent suggérer une potentielle asso-
ciation entre ces deux entités et leurs implications, principalement dans le risque d’accident
vasculaire cérébral.
© 2011 Elsevier Masson SAS. Tous droits réservés.
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PFO and OSA, both of which are common in the general popu-
lation, have mostly been studied separately. During the past
decade, several studies suggesting an association between
PFO and OSA have been published. Our aim is to provide
clinicians with a review of all the available data concerning
this potential association.
First, we will deﬁne PFO and OSA, and summarize the
available epidemiological data. The diagnostic criteria and
the techniques of detection are discussed. We will then
focus on the interesting potential pathophysiological links
between PFO and OSA, which should encourage recognition
of this association. The speciﬁc case of stroke is discussed as
a potential dangerous consequence of this association. We
conclude with the clinical implications and possible future
treatment strategies.
Patent foramen ovale: deﬁnition and
epidemiology
PFO is an embryological remnant of the foetal circulation
caused by incomplete fusion of the septum primum and
secundum. This valve-like opening represents the most fre-
quent interatrial communication. The prevalence of PFO is
9.2—24.3% based on TOE [1—3], 10—18% on TTE [4,5], and
14.6—27.3% on autopsy studies [6,7]. Based on all available
series, the prevalence of PFO in the general population is
estimated to be 10—30%. The prevalence of PFO decreases
with age, from 34.3% during the ﬁrst three decades of life to
20.2% during the ninth and tenth decades [6]. However, the
size of the foramen tends to increase with age, suggesting
that small PFO may seal with time [6].
In most cases, PFO remains asymptomatic, but it may
also have important clinical consequences. No speciﬁc symp-
toms, other than the POS in severe cases, are directly
related to PFO, but when right atrial pressure exceeds
left atrial pressure (e.g. Valsalva), right-to-left shunting
may occur, allowing venoarterial (‘‘paradoxical’’) systemic
embolization and passage of deoxygenated blood in the left
atrium.
Patent foramen ovale and associated diseases
Despite numerous studies, a direct relationship between
paradoxical embolization through PFO and stroke remains
difﬁcult to prove. A meta-analysis of case-control stud-
ies in patients with otherwise unexplained (‘‘cryptogenic’’)
stroke showed, in 2000, that PFO was more prevalent in such
patients, particularly in the young [8]. Another more recent
u
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Y
atudy extended this observation to patients > 55 years of age
ho suffered stroke (28.3% vs 11.9%; P < 0.001) [9].
It has not, however, been possible to show that patients
ho have never had a stroke are at increased risk for a ﬁrst
vent in the presence of a PFO and/or an ASA [2,3,10]. This
ay be due to the low relative stroke risk of a PFO compared
ith other stroke risk factors. Larger cohorts with longer
ollow-up would therefore be required to show such a corre-
ation [11]. The risk of recurrence after a cryptogenic stroke
s also lower than after cardiac embolism (e.g. atrial ﬁbril-
ation) or after stroke due to large artery atherosclerosis.
oreover, it has been difﬁcult to prove that patients with
PFO and otherwise cryptogenic stroke have an increased
ecurrence risk [12]. The risk of recurrence after crypto-
enic stroke might even be the same as in a patient without
FO. Finally, the presence of an ASA, a large right-to-left
hunt, and the coexistence of prothrombotic states seems
o increase the association between PFO and cryptogenic
troke, but this has not been uniformly proven [13—18].
The potential correlation between migraine and PFO
s also intensely debated, and illustrates the difﬁculty in
ssessing an association between PFO and another deﬁnite
athology with epidemiological studies. The prevalence of
FO in patients who have migraine with aura seemed to be
igher (28—48%) than in controls [19—25]. After encourag-
ng reports in case series indicating a potential beneﬁt on
igraine recurrence after PFO closure [26], the ﬁrst ran-
omized, prospective, sham-control trial could not conﬁrm
hese effects [20].
PFO has also been implicated in decompression sickness.
ivers with PFO have a higher load of small ischaemic brain
esions [27]. Also, the prevalence of PFO in divers who have
lready experienced a major event of decompression illness
s higher than in divers who have not; and small PFO seem
o present less risk of decompression illness [28,29].
bstructive sleep apnoea: deﬁnition and
pidemiology
SA is a common sleep disorder, described as repeated clo-
ure of the upper airway during sleep. The obstruction may
e due to: a decreased activity of the pharyngeal muscu-
ature; pharyngeal fat deposits; and mucosal inﬂammation
eading to occlusion or near occlusion of the upper airway
30,31]. OSA is usually deﬁned as more than ﬁve episodes
f apnoea or hypopnoea per hour of sleep. The AHI is
sually used to assess the severity of sleep apnoea (mild:
—15; moderate: 15—30; severe > 30 events/h) [32,33].
oung et al. studied a middle-aged population and described
prevalence of OSA (AHI≥ 5) of 9% inwomen and 24% in men
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34]. Patients with sleep apnoea syndrome have AHI≥ 5 and
ymptoms during the day, principally hypersomnolence due
o sleep fragmentation. The prevalence of this syndrome in
he study by Young et al. was 2% in women and 4% in men
34]. It is also associated with an increased incidence of
ypertension, cardiovascular disease and trafﬁc accidents
35—39]. OSA has also been reported in association with
octurnal arrhythmias and stroke [40,41]. OSA is frequently
ndiagnosed, leading to a substantial cardiovascular mor-
idity.
bstructive sleep apnoea and risk of stroke
ase-control and cross-sectional studies have shown an asso-
iation between snoring and cardiovascular disease [42,43].
n association between sleep-disordered breathing and
troke has also been evoked for many years [39,44,45]. In
005, Arzt et al. published cross-sectional and longitudi-
al analyses of 1475 members of the general population
46]. They found that an AHI≥ 20 increased the chance of
troke compared to an AHI≤ 5 (OR 4.33, 95% CI 1.32—14.24;
= 0.02) [46]. In the prospective part of the study (n = 1189),
he adjusted OR for a ﬁrst-ever stroke in the subsequent
years in a patient with AHI≥ 20 vs≤ 5 was 3.08 (P = 0.12)
46]. Although the strong correlation between OSA and car-
iovascular disease may in part be due to overlapping risk
actors for atherosclerosis [47], there is evidence that OSA is
n independent risk factor considering the potential mech-
nisms increasing the risk of stroke in OSA patients [41].
Several hypotheses may explain the increased risk of
troke in OSA patients [48—50]. Hypoxaemia and decreased
erebral perfusion pressure (due to increased intracranial
ressure at the end of the apnoea) are considered to be
eterminants of cerebral nocturnal ischaemia. Haematolog-
cal parameters may also play a role, such as enhanced
latelet aggregation, increased viscosity, and higher ﬁbrino-
en concentration [48,50—53]. This increase in ﬁbrinogen
ay decrease with CPAP [54]. Cardiac arrhythmias are more
requent in OSA patients, particularly atrial ﬁbrillation,
hich is a risk factor for stroke [55,56].
iagnosis
he prevalence of a disease is dependent of the deﬁnition
nd the technique of detection used [57]. The choice of the
iagnostic tool and a strict protocol are crucial to diagnose
FO and OSA.
iagnosis of patent foramen ovale
FO is usually diagnosed with TTE or TOE, with injection of
gitated saline contrast to create microbubbles. Contrast
OE is considered as the gold standard. The deﬁnition of
FO is based on echocardiographical criteria: ≥ 3 bubbles
≥ 1 according to some authors) must be observed in the
eft atrium within three cardiac cycles after the entry of
he bubbles in the right atria. Direct visualization of bubbles
assing through the PFO channel may also be considered as
roof of PFO.
The sensitivity of microbubble assessment of PFO is
ncreased by provocative manoeuvres such as cough [58]
c
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nd voluntary Valsalva [5,59]. At the end of Valsalva strain,
transient pressure elevation inside the right-sided car-
iac chambers is observed, increasing the likelihood of a
ight-to-left interatrial shunting. A correct Valsalva manoeu-
re is crucial and the patient must receive appropriate
nstructions before the test. A leftward displacement of the
nteratrial septum indicates a higher right than left atrial
ressure [60]. Increasing the number of injections, and early
ather than late Valsalva, is more effective [61]. Usually,
njection of contrast is performed antecubitally, but femoral
njection has also been used [62].
Contrast-enhanced transcranial Doppler is also a valuable
ool for PFO diagnosis, allowing noninvasive examination
f the middle cerebral artery with good sensitivity and
peciﬁcity. It is considered as efﬁcient as echocardiographic
echniques (evidence level type A, class II) [63]. This tech-
ique allows the examination of patients while asleep.
owever, it does not allow differentiation of the source
f shunting (intrapulmonary or intracardiac) or provide any
nformation on the morphology of the interatrial septum
e.g. ASA) and on other intracardiac source of embolization
e.g. thrombus) [64—68].
iagnosis of obstructive sleep apnoea
he gold standard method for the diagnosis of OSA
s polysomnography: electroencephalogram, electrocardio-
ram, electrooculogram, submental and tibial electromyo-
rams, body position detector, nasal pressure recording (or
n oronasal thermistor), pulse oximeter, and belts to mon-
tor movements of the chest wall and abdomen. In some
uropean countries, and recently in the USA, limited chan-
el home monitoring (type III) is considered as a suitable
lternative when pretest clinical suspicion of OSA is high.
his type of monitoring is much cheaper and more conve-
ient (as it can be performed at home), but is less accurate
s there is no electroencephalogram.
oexistence of patent foramen ovale and
bstructive sleep apnoea
wing to their high prevalence in the general population,
t is evident that PFO and OSA may coexist fortuitously in
any patients. A strict methodology is thus required to
ssess a potential relationship between PFO and OSA to avoid
ias. The controversies observed in the studies concerning
troke and migraines are an important illustration of this
roblem. Two studies have speciﬁcally examined the preva-
ence of PFO in OSA patients. Both concluded that PFO is
ore frequent in patients with OSA than in controls, but
ith important differences in their results. The ﬁrst study,
onducted by Shanoudy et al., used TOE in 72 awake male
atients [69]. They detected 33 PFO in 48 patients with OSA
nd four PFO in 24 controls (68.8% vs 16.7%; P < 0.001) [69].
n this study, mean AHI was 33.9; and mean pulmonary artery
ystolic pressure was higher in patients with OSA than in
ontrols. This study also revealed that one-third of patients
ith OSA and PFO had a signiﬁcant decrease in oxygen arte-
ial saturation after Valsalva, suggesting that a right-to-left
hunting occurred and that PFO may contribute to hypox-
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aemia [69]. The methodology of this study was criticized,
regarding patient selection and exclusion criteria [70].
In the second study, Beelke et al. studied 78 patients
with OSA and 89 controls using transcranial Doppler [71].
All subjects with OSA had AHI > 10 during polysomnography,
and the mean± SD AHI was 52± 25 [71]. PFO was found
in 21/78 patients with OSA (26.9%) versus 13/89 controls
(14.6%; P < 0.05) [71]. Among patients with OSA, 85% only
presented PFO during Valsalva.
Considering these two studies, it is possible to believe
that the prevalence of PFO might be higher in OSA patients.
However, in the second study [71], the percentage of
patients with OSA and PFO (26.9%) is close to the percent-
age found in the general population in other epidemiological
studies. The small size of these studies, the difference of
patient selection, and the technique of detection is clearly
insufﬁcient to demonstrate a direct correlation between
these two pathologies, and larger epidemiological studies
are now required.
Moreover, these studies only show an association rather
than a causal relation, and do not answer the questions of
whether OSA increases the risk of PFO or whether PFO is a
risk factor itself for OSA. Furthermore, no precise data on
stroke before or after the diagnosis of OSA and PFO were
presented in these studies.
Pathophysiological interactions between
obstructive sleep apnoea and patent
foramen ovale
Several pathophysiological interactions exist between OSA
and PFO (Fig. 1). OSA is the consequence of repeti-
tive pharyngeal collapse while diaphragmatic efforts are
maintained. At ﬁrst, an obstructive apnoea may be assim-
ilated to a Muller manoeuvre (inspiration effort against a
closed upper airway), which can provoke severe negative
intrathoracic pressure as low as −80 cm H20 [72]. If the
[
t
s
hobstructive sleep apnoea; PFO: patent foramen ovale).
bstruction persists, alternating sequences of Muller and
alsalva manoeuvres may be undertaken, leading to impor-
ant intrathoracic pressure variations. Enhanced venous
eturn is observed when intrathoracic pressure decreases,
eading to repetitive transient pressure and volume eleva-
ion in the right heart, predisposing to right-to-left shunting
71]. Shiomi et al. undertook TTEs during the sleep of
pnoeic patients, and observed a leftward shift of the
nterventricular septum during the apnoea in half of their
atients, all presenting the lowest intrathoracic pressure
uring the apnoea periods [72]. This shift was correlated
ith a decrease in arterial blood pressure during inspira-
ion, called a pulsus paradoxus (as described in cardiac
amponade), explained through an interdependence mech-
nism limiting left ventricular ﬁlling [72]. Pulsus paradoxus
as more frequent in younger people who could develop
ore negative inspiratory oesophageal pressure [73]. Inter-
stingly, CPAP limits the variations of intrathoracic pressure
nd abolishes these interdependence mechanisms and the
ulsus paradoxus [72].
Normally, blood pressure and cardiac output decrease
uring sleep. During an apnoea, blood pressure progressively
ncreases and reaches its peak value after the apnoea, due to
ypoxaemia, transient hypercapnia and awakening (sympa-
hetic discharge). Pulmonary pressure also increases when
ypoxaemia and hypercapnia occur [74]. Cardiac output may
all by up to 33% during the apnoea, and then increase above
he baseline values when normal ventilation is restored [75].
t the beginning of the apnoea, the increase in parasympa-
hetic tone may lead to bradyarrhythmias. After the apnoea,
he increase in sympathetic tone may lead to arrythmia like
trial ﬁbrillation [74,76—78]. Patients with OSA conserve a
igher sympathetic activity during the day than controls,
hich is a risk factor for developing future hypertension
36,79]. Conversely, OSA itself only plays a minor role in
he development of chronic pulmonary artery hyperten-
ion compared to associated obstructive disease or chronic
ypoxaemia [80].
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ight-to-left shunting
eft atrial pressure is normally higher than in the right
trium, but the gradient may be reversed allowing right-
o-left shunting. Shunting through PFO is not frequent
t rest, but may increase with voluntary manoeuvres
ike Valsalva or during activities of daily life (coughing,
inging, sexual intercourse, weight lifting). The gradient
etween the atria may also be reversed in the case of
SA [69,81], severe chronic obstructive pulmonary disease
82] or pulmonary embolism [83,84]. The ﬂow through the
FO also depends on: the size of PFO, the right ven-
ricular function, and the function of the tricuspid valve
85].
It has been speculated that the increased prevalence
f PFO in OSA patients could be attributed to recurrent
levation of pressure in the right heart observed during
pnoea [69]. Beelke et al. demonstrated that obstructive
pnoea itself may provoke a right-to-left shunt [81]. They
tudied 10 patients with OSA and PFO (which was present
nly during Valsalva). In nine patients, a right-to-left shunt
as detected with transcranial Doppler during sleep, but
nly after OSAs lasting≥ 17 s [81]. This demonstrates that
ight-to-left shunting may occur during sufﬁciently long
pnoeas through PFO that are ‘silent’ the rest of the time
81].
ypoxaemia
n OSA, oxygen desaturation and hypoxaemia are gener-
lly attributed to the apnoeas themselves. During apnoea,
lveolar ventilation is compromised, leading to transient
ypoxaemia, hypercapnia and acidosis [74,76]. However,
mportant variations of nocturnal hypoxaemia have been
bserved in patients with the same degree of OSA. Bradley
t al. showed that desaturation was related to oxygen sat-
ration at the beginning of the apnoea, the length of the
pnoea and the lung volume at which the apnoea occurred
86]. Hypoxaemia may also accentuate the sensitivity of
O2 chemoreceptors, increasing ventilatory instability [87].
t also increases pulmonary artery pressure due to hypoxic
ulmonary vasoconstriction. Finally, hypoxaemia may play
role in oxidative stress and endothelial dysfunction,
ccelerating atherosclerosis [88,89]. PFO is of no clinical
igniﬁcance in most patients, but some patients may suf-
er from hypoxaemia due to the passage of deoxygenated
lood from the right to the left atria. This is particu-
arly seen in the rare cases of large PFOs, leading to
OS.
In patients with OSA, the coexistence of a PFO may poten-
ially worsen hypoxaemia and increase the risk of ventilatory
nstability. Johansson et al. have shown that right-to-left
hunting through PFO may contribute to oxygen desatu-
ation in these patients [90]. They compared 15 patients
ith high proportional desaturation with 15 controls with
ow proportional desaturation. Nine patients (60.0%) in the
rst group and two (13.3%) in the second group had a large
FO (P = 0.02) [90]. They concluded that oxygen desatura-
ion occurred more frequently in OSA patients presenting
PFO, taking into account the respiratory disturbances
90].
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atent foramen ovale and obstructive sleep
pnoea: a combined risk factor for stroke?
ome authors have described stroke in patients with coex-
sting PFO and OSA [91,92]. Ozdemir et al. studied 175
atients with cryptogenic strokes and reported that 15
16.8%) patients with PFO woke up with stroke or TIA, which
s more frequent than in patients without PFO (5%; P = 0.009)
93]. They hypothesized that OSA could contribute to this
henomenon [93].
PFO potentially enables venoarterial embolization, and
SA predisposes patients to right-to-left shunting through
he PFO. The risk of stroke could therefore be cumula-
ive, through different mechanisms associated with PFO
nd OSA (Fig. 2). Some authors have already proposed
hat PFO should be sought in patients with OSA, in order
o recommend an appropriate prevention for stroke, using
harmacological treatment or PFO closure [81].
reatment
reatment of patent foramen ovale
hether to treat PFO is determined by the clinical pre-
entation. The majority of patients with PFO will never be
ymptomatic, and treatment is not required. Prevention of
ecurrent stroke is the primary goal of PFO treatment. Treat-
ent of hypoxaemia due to right-to-left shunting and POS
re of minor importance.
A very careful work-up by stroke experts needs to be
erformed before implicating the PFO as a cause. Other
auses are much more frequent, and certainty of causality
an only rarely be established. Furthermore, the recurrence
isk related to a PFO remains doubtful [12], as already men-
ioned. Conventional risk factors should be actively sought
nd treated in any stroke patients, including OSA.
If PFO is considered a probable causal factor in a TIA or
troke, and the recurrence risk is considered elevated, cur-
ent possibilities to prevent PFO-related recurrences are:
edical treatment with antiplatelet agents or anticoagu-
ants, and surgical or percutaneous PFO closure. Despite
umerous publications, there remains no consensus on PFO
reatment and indications of percutaneous closure.
The ﬁrst report of percutaneous closure of an atrial septal
efect was in 1976 [94]. Since then, many different devices
ave been developed. In the context of previous cerebrovas-
ular events, percutaneous closure has been described since
992 for secondary prevention [95]. Surgical closure has also
een reported in the 1990s [96,97]. As the development
f percutaneous closure progressed rapidly, the number of
urgical closures has declined.
Percutaneous closure is minimally invasive, has a low
orbidity rate, and has a high success rate [98,99]. It allows
he cessation of medication after 6months if a high likeli-
ood of a causal link between PFO and the cerebrovascular
vent has been established by stroke experts, and if other
isk factors are absent. Given that the presence of an ASA in
ssociation with a PFO has been described to increase the
isk of recurrent stroke compared to ASA or PFO alone in
ome studies, it was important to show that percutaneous
losure can also treat this condition [100].
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AHA guidelines state that an antiplatelet agent is rec-
ommended after non-cardioembolic ischaemic stroke (Class
I, level of evidence A) [101]. After ischaemic stroke in
patients with PFO, an antiplatelet agent is also recom-
mended (Class IIa, level of evidence B) [101]. It remains
unclear whether anticoagulation is superior to antiplatelet
treatment in these patients [13,18], and an appropriate trial
has not been performed to date. The ESO considers anticoag-
ulation an option in stroke patients with PFO in the presence
of proven deep vein thrombosis or ASA (Class IV, good clinical
practice) [102].
As described above, the risk of recurrent cerebrovascu-
lar event related to a PFO probably depends on numerous
other factors (concomitant ASA, size of PFO, spontaneous
right-to-left shunting, recurrent strokes, hypercoagulabil-
ity disorders, or vein thrombosis), which may be taken into
account on an individual basis and after multidisciplinary
discussion.
Regarding percutaneous closure, the indications are very
restrictive in the USA. The FDA accepted percutaneous
closure when medical treatment failed for secondary pre-
vention of stroke, i.e. after a recurrent stroke [103]. The
AHA guidelines edited in 2006 stated that insufﬁcient data
were available to propose PFO closure after a ﬁrst stroke
(Class IIb, level of evidence C) [101]. Nowadays, occlud-
ers are available under an FDA-approved investigational
device exemption. The ESO considers endovascular clo-
sure an option in patients with cryptogenic stroke and
high-risk PFO, for instance with concomitant ASA (Class IV,
GCP) [102]. The results of the CLOSURE I trial were pre-
sented at the AHA late-breaking clinical trial session (AJ
Furlan et al. Chicago, IL, 15 November 2010). Closure I
is a prospective, multicentre, randomized controlled trial
comparing PFO closure with best medical therapy involving
909 patients < 60 years of age with a cryptogenic stroke or
a
r
y
cp apnoea; PFO: patent foramen ovale).
TIA and a PFO. Of these, 447 patients had percutaneous
FO closure with STARFlex and 462 received optimal medi-
al treatment. Two years after randomization, no difference
as observed between the two groups in terms of stroke and
IA. The incidence of stroke was 12 (3.1%) in the PFO clo-
ure group versus 13 (3.4%) in the medically treated group
P = 0.77), whereas TIA was observed in 13 (3.3%) and 17
4.6%) patients, respectively, in each group (P = 0.39). Thir-
een major complications (3.2%) were reported after PFO
losure whereas none were reported with medical treatment
P < 0.001). This ﬁrst study failed to demonstrate superior-
ty of PFO closure over medical treatment in preventing
troke or TIA recurrence. More importantly, a higher rate
f complications was observed in the device group.
Other ongoing randomized studies are currently inves-
igating the role of device closure in the prevention of
ryptogenic stroke and TIA recurrence (CLOSE, PC-trial,
ESPECT). Of note, the recurrence rate of stroke in patients
ith previous cryptogenic stroke is low on medical therapy.
his may partially explain the negative results of CLOSURE
as more patients and a longer follow-up may have been
eeded to reach a sufﬁcient power of analysis.
reatment of obstructive sleep apnoea
onservative treatment (e.g. weight loss and discontinua-
ion of alcohol and sedatives) is recommended to all OSA
atients and may, in some individuals, be sufﬁcient to treat
he disease. However, CPAP is the treatment of choice for
SA. Therapies must be based on the symptoms of the
atient (daytime somnolence), the severity of OSA (AHI)
nd the presence of cardiovascular comorbidities [104]. A
ecent observational study with a mean follow-up of 10.1
ears showed that the risk of fatal and nonfatal cardiovas-
ular events was increased in men with severe OSA (AHI > 30)
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Table 1 Effects of continuous positive airway pressure
(CPAP).
Decrease of ﬂuctuations of intrathoracic pressure
Restoration of venous return
Abolishment of interdependence mechanisms and pulsus
paradoxus
Reduction in blood pressure during the day and night
Attenuation of sympathetic activity
Reduction of pulmonary artery pressure during apnoea
Reduction in the risk of cardiovascular events
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ing stroke. In our opinion, a thorough investigation of OSAImprovement of endothelial dysfunction
r with an AHI of 5—30 and daytime sleepiness compared to
ontrols [37]. This study also demonstrated that treatment
ith CPAP reduced the risk of cardiovascular events in severe
SA patients. This should encourage more clinicians to rec-
gnize OSA, and to propose appropriate treatment that may
ecrease mortality [104,105].
CPAP decreases ﬂuctuations of intrathoracic pressure and
estores a normal venous return during sleep, allowing a
ecrease of right-to-left shunting through PFO. Treatment
ith CPAP also attenuates nocturnal and daytime sympa-
hetic activity and decreases systemic blood pressure and
ulmonary pressure (Table 1) [79,106]. Becker et al. fol-
owed apnoeic patients efﬁciently treated with CPAP, and
bserved a reduction in blood pressure during the day and
he night [106].
A recent prospective study by Martinez-Garcia et al.
howed that long-term CPAP treatment in patients with mod-
rate to severe OSA (AHI≥ 20) who suffered from ischaemic
troke is associated with a reduction in mortality [107].
hey compared the clinical evolution of 68 patients with
HI≥ 20 who did not tolerate CPAP to 70 patients with
HI < 20 and to 28 patients with AHI ≥ 20 who tolerated CPAP.
he patients with AHI > 20 who did not tolerate CPAP had a
igher risk of mortality compared with the other two groups
HR 2.69, 95%CI 1.32—5.61; P = 0.009) and HR 1.58, 95%CI
.01—2.49; P = 0.04, respectively [107]. These studies con-
rm that effective treatment of OSA may improve prognosis
f patients, particularly those with previous stroke.
erspectives of treatment in cases of
oexistence of patent foramen ovale and
bstructive sleep apnoea
case of spectacular improvement of OSA after closure of
FO has been described by Silver et al. [108]. A 51-year-old
an admitted for a cryptogenic stroke had a PFO closure.
is AHI dropped from 189 (181 apnoeas and 8 hypopnoea)
o 19 apnoeas/hour after closure. The patient also reported
signiﬁcant improvement in his symptoms of daytime som-
olence. No weight loss or medication changes were noted
108].
Agnoletti et al. reported another case of a 42-year-old
an with severe OSA with AHI of 44 and spontaneous right-
o-left shunt through PFO seen with TOE [109]. This patient
as initially treated with CPAP, which improved his AHI to
, but the patient still had fatigue, dyspnoea, and desat-
ration on exertion. Finally, percutaneous closure of the
s
f
tC. Pellaton et al.
FO was performed, allowing complete resolution of symp-
oms [109]. Pinet and Orehek reported a case of a patient
ith severe OSA (AHI 82) and right-to-left shunting through
PFO [110]. The shunt was demonstrated by transcranial
oppler and conﬁrmed with TOE. After 1 week of CPAP,
is AHI dropped to 3. Further transcranial Doppler analy-
is did not show any passage of microbubbles during normal
reathing, suggesting the absence of shunt at rest. Shunt
as nevertheless still present during Valsalva [110].
Some assumptions can be made from these few anecdo-
al cases. First, percutaneous closure of PFO decreases the
assage of deoxygenated blood in the left atria. This limits
ntermittent hypoxaemia and the risk of periodic breathing
hat may aggravate OSA. Passage of neurohumoral mediators
hrough PFO triggering OSA has also been evoked, but has
ever been proven. Secondarily, CPAP limits the variation
f intrathoracic pressure and diminishes hypoxaemia and
rterial pulmonary pressure, thus decreasing right-to-left
hunting.
ummary and conclusions
espite variations in different studies, the prevalence of
FO in the general population may be considered as high
10—30%). With a prevalence of 9% in women and 24% in men,
SA is also a common disorder. It is thus easy to suggest that
umerous patients present both PFO and OSA. Actual avail-
ble epidemiological data are insufﬁcient to demonstrate a
orrelation between PFO and OSA, but suggest an increase
f prevalence of PFO in OSA patients.
PFO is usually asymptomatic and OSA also remains
requently undiagnosed. This explains the fact that the asso-
iation of both of these pathologies is poorly known and
ittle studied. Only one very recently published review has
ddressed this question [111].
OSA and PFO have both been independently suspected
o increase the risk of stroke, but their association has
ever been speciﬁcally studied. Even though PFO remains
symptomatic in most cases, right-to-left shunting may
avour paradoxical systemic embolization and is considered
s a potential risk factor for stroke. OSA also confers an
ncreased incidence of hypertension, nocturnal arrhythmias
nd haematological disturbances, thus increasing the risk
f stroke and cardiovascular morbidity. OSA leads itself to
esaturation and hypoxaemia, which may be aggravated
y PFO due to right-to-left shunting. Right-to-left shunt-
ng through the PFO is favoured by elevation of pressure
n the right atrium created by apnoeas and is reinforced by
ypoxic pulmonary vasoconstriction. Therefore, it is possi-
le to hypothesise that the association of PFO and OSA might
reate a cumulative risk for stroke, and that PFO may be an
ggravating factor in OSA, increasing the risk of periodic
reathing.
In the future, large epidemiological studies should assess
he association of PFO and OSA in patients to determine
heir risk of stroke. The role of PFO closure in these patients
hould also be studied to determine its efﬁciency in prevent-hould be performed in patients with PFO who have suffered
rom stroke in order to decide on the appropriate preven-
ion. We are not advocating investigation of PFO in all OSA
Patent foramen ovale and obstructive sleep apnoea
patients, except for those who have presented with a stroke
or a TIA.
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